References
- World Health Organization (WHO). Pneumonia of unknown cause. Geneva: WHO; 2020. Available from: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/
- Zhou P, Yang XL, Wang XG, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020. Available from: https://www.biorxiv.org/content/early/2020/01/23/2020.01.22.914952
- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574.
- Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127.
- Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.
- Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020.
- Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448.
- Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
- Menachery VD, Yount Jr BL, Debbink K, et al. Corrigendum: a SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2016;22:446.
- Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34.
- Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25:2000058.
- Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64:e00399–20.
- Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020;12:269–273.
- Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25:551–557.
- Horisberger A, La Rosa S, Zurcher JP, et al. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer. 2018;6:156.
- Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55:105954.
- Raimondo MG, Biggioggero M, Crotti C, et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–1603.
- Grabowski T, Burmańczuk A, Miazek A. Effect of siltuximab, omalizumab, infliximab, pembrolizumab and vedolizumab on selected haematological and biochemical parameters in a pig model. Pol J Vet Sci. 2020;23:51–58.
- Ramírez J, Cañete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018;17:727–732.
- Yalcin AD, Yalcin AN. A case of Asthma with Behcet’s disease: successful treatment with Omalizumab and its effects on recurrent aphthous lesions. Immunopharmacol Immunotoxicol. 2020;42:379–382.
- Yalcin AD, Uzun R, Yalcin AN, et al. Omalizumab treatment in bronchiectasis with allergic Asthma: long-term follow up. Oral presentation. [SS-143]. TÜSAD 41. Uluslararası Katılımlı Ulusal Kongresi SOLUNUM. 2019. Available from: https://www.abstractagent.com/2019solunum/?plng=eng
- Yalcin AD, Cilli A, Bisgin A, et al. Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels. Expert Opin Biol Ther. 2013;13:1335–1341.
- Yalcin AD, Uçar S, Gumuslu S, et al. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter’s syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol. 2013;35:524–527.
- Yalcin AD, Uzun R. Anti-IgE significantly changes circulating interleukin-25, vitamin-D and interleukin- 33 levels in patients with allergic Asthma. Curr Pharm Des. 2019;25:3784–3795.
- Yalcin AD. A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacol Immunotoxicol. 2016;38:162–166.
- Yalcin AD, Celik B, Gumuslu S. D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment. Expert Opin Biol Ther. 2014;14:283–286.
- Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL-10, TGF-β, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm. 2012;2012:720976.
- Yalcin AD. Advances in anti-IgE therapy. Biomed Res Int. 2015;2015:317465.
- Uzun R, Didem Yalcin A, Celik B, et al. Levofloxacin induced toxic epidermal necrolysis: successful therapy with omalizumab (Anti-IgE) and pulse prednisolone. Am J Case Rep. 2016; 17:666–671.
- Yalcin AD, Gumuslu S, Parlak GE, et al. Systemic levels of ceruloplasmin oxidase activity ın allergic asthma and allergic rhinitis. Immunopharmacol Immunotoxicol. 2012;34:1047–1053.
- Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of Asthma. Am J Respir Crit Care Med. 2017;196:985–992.
- He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26:672–675.
- Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med. 2020;26:676–680.
- Efthimiou J, Poll C, Barnes PJ. Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation. Eur Respir J. 2019;54:1802390.
- Gill MA, Bajwa G, George TA, et al. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol. 2010;184:5999–6006.
- Durrani SR, Montville DJ, Pratt AS, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol. 2012;130:489–495.
- Wark PAB, Nichol K, Dorahy D, et al. The effect of treatment with omalizumab on anti-viral responses in adults with severe allergic asthma. Am J Respir Crit Care Med. 2018;197:A6166.
- Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20:269–270.
- Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with covid-19 – a case series. N Engl J Med. 2020;382:2478–2480.
- Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013;497:498–502.
- Perrin-Cocon L, Aublin-Gex A, Sestito SE, et al. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep. 2017;7:40791.
- Piao W, Shirey KA, Ru LW, et al. A decoy peptide that disrupts TIRAP recruitment to TLRs is protective in a murine model of influenza. Cell Rep. 2015;11:1941–1952.
- Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–312.
- Epidemiology Working Group for NCIP Epidemic Response The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol. 2020;41:145–151.
- Taneja V. Sex hormones determine immune response. Front Immunol. 2018;9:1931.
- Liu A. China turns Roche arthritis drug Actemra against COVID-19 in new treatment guidelines. Fierce Pharma; 2020. Available from: https://www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines
- Roivant Sciences. Roivant announces development of anti-GM-CSF monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19. Roivant Sciences; 2020. Available from: https://roivant.com/roivant-announces-development-of-anti-gm-csf-monoclonal-antibody-to-prevent-and-treat-acute-respiratory-distress-syndrome-ards-in-patients-with-covid-19/
- Humanigen. Humanigen partners with CTI, a leading contract research organization, for planned phase III study for lenzilumab for coronavirus treatment. Humanigen; 2020. Available from: https://www.humanigen.com/press/Humanigen-Partners-With-CTI%2C-A-Leading-Contract-Research-Organization%2C-For-Planned-Phase-III-Study-For-Lenzilumab-For-Coronavirus-Treatment
- Izana Bioscience. Initiation of two-centre compassionate use study involving namilumab in the treatment of individual patients with rapidly worsening COVID-19 infection in Italy. Izana Bioscience; 2020. Available from: https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/
- Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–474.
- Prete M, Favoino E, Catacchio G, et al. SARS-CoV-2 inflammatory syndrome. Clinical features and rationale for immunological treatment. Int J Mol Sci. 2020;21:3377.
- Mihai C, Dobrota R, Schroder M, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020;79:668–669.
- Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 2020;15:247–249.
- Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab.
- Marovich M, Mascola JR, Cohen MS, et al. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324:131.
- Ronconi G, Teté G, Kritas SK, et al. SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines. J Biol Regul Homeost Agents. 2020;34.
- Conti P, Gallenga CE, Tetè G, et al. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents. 2020;34:333–338.
- Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34:339–343.
- Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents. 2020;34.
- Franza L, Carusi V, Altamura S, et al. Interrelationship between inflammatory cytokines (IL-1, IL-6, IL-33, IL-37) and acquired immunity. J Biol Regul Homeost Agents. 2019;33:1321–1326.
- Caraffa A, Gallenga CE, Kritas SK, et al. CAR-T cell therapy causes inflammation by IL-1 which activates inflammatory cytokine mast cells: anti-inflammatory role of IL-37. J Biol Regul Homeost Agents. 2019;33:1981–1985.